Forrester’s Snow saw it differently. “Flatiron is more like an information service provider and less like a Sloan Kettering or Icahn,” he said. “The Sloan Ketterings and Icahns are saying, ‘We are the centers of excellence, the creators of the protocols and the content, and we will sell you the license to have access to our model of excellence.’ “
不过斯诺的看法有所不同。他说:“Flatiron更像是个信息服务提供商,而不像斯隆o凯特灵和伊坎这类专业研究机构。而斯隆o凯特灵和伊坎会说‘我们是专业卓越的中心,行业标准的起草者,我们为您提供授权,使您也能用上我们的卓越模式。’”
Flatiron, on the other hand, “wants to be the Lexis-Nexis of cancer,” Snow said. “Aggregate the data, store it, and license it to the community with tools so you can ask the questions you need to ask.”
而另一方面,斯诺表示,Flatiron的目标是“在癌症研究领域成为像Lexis-Nexis(美国顶级商业与法律数据库——译注)一样的顶级数据库。它主要业务就是收集数据、存储数据,再将数据和相关工具授权给相关研究机构,使其能咨询相关问题。”
Which means the company is better suited to compete with Bloomberg, Lexis-Nexis (owned by Reed Elsevier), IMS Health, and Thompson-Reuters rather than organizations trusted on the subject on cancer like Sloan Kettering.
【科技是否万能 大数据能够战胜癌症吗】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15